ArticleCancers2025

Design of a Phase I Drug Combination Study with Adaptive Allocation Based on Dose-Limiting Toxicity Attribution.

Nolan A Wages et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.